RNAC Stock Analysis: Why Analysts See 391% Upside Potential

Cartesian Therapeutics (RNAC) just got a fresh Buy rating from HC Wainwright & Co., and the numbers are turning heads. Here’s what’s actually happening:

The Bull Case

Analysts are pricing in massive growth. The average price target sits at $37.45/share, implying a 391% jump from the current $7.62. That’s not small talk—it suggests the market is severely undervaluing the biotech story here.

What’s driving it? Revenue projections are exploding: $43MM annually, a staggering 3,803% increase. Translation: this is a pre-revenue or early-stage revenue company about to scale hard.

The Institutional Angle

Here’s where it gets interesting. While analyst sentiment is bullish, big money is actually pulling back:

• FBIOX (Biotech Portfolio) dumped 13.43% of its position last quarter, cutting allocation by 47.86%
• MPM Oncology Impact Management was even more aggressive—slashed holdings by 80.53%, cutting portfolio weight by 48.52%
• Only Siren, L.L.C. held steady with 563K shares

Total institutional ownership actually dropped 5.96% to 6.7M shares, even as 173 funds/institutions hold positions.

The Red Flag

This divergence matters. Smart money is de-risking while analysts pump the price target. The put/call ratio of 0.32 is bullish on paper, but that insider selling tells a different story. Is this a setup where retail chases the narrative while institutions lock in gains?

Bottom Line

RNAC looks like a classic binary bet: transformative biotech with massive upside if the revenue projections pan out. But the fact that seasoned biotech funds are trimming positions while analysts are bullish? That’s the tension you need to watch.